Literature DB >> 12766126

Ulcer recurrence following first ray amputation in diabetic patients: a cohort prospective study.

Luca Dalla Paola1, Ezio Faglia, Maurizio Caminiti, Giacomo Clerici, Sasa Ninkovic, Valter Deanesi.   

Abstract

OBJECTIVE: To evaluate the reulceration and reamputation rates in a cohort of diabetic patients following first ray amputation. RESEARCH DESIGN AND METHODS: We evaluated a cohort of 89 diabetic patients, 63 men and 26 women, who underwent first ray amputation in the period from January 2000 to December 2001. The first ray lesions were Wagner grade 2 in 3 patients, Wagner grade 3 in 47 patients, and Wagner grade 4 in 39 patients. Following surgical wound healing, all patients wore special footwear with rocker bottom soles and custom molded insoles and were put on an intensive secondary prevention program.
RESULTS: The mean follow-up duration was 16.35 +/- 6.76 months (range 7-28). Fifteen patients developed new ulcerations, with 11 lesions occurring ipsilaterally and 4 contralaterally to the first ray amputation. In seven patients, the new lesion was treated and healed with dressing. Eight patients underwent a new surgical procedure: panmetatarsal head resection in four patients, toe amputation in two patients, a transmetatarsal amputation in one patient, and Lisfranc's amputation in one patient.
CONCLUSIONS: In the population studied, the first ray amputation presented a lower reulceration and reamputation rate with respect to that reported in the literature. This finding should therefore be attributed to the follow-up program, which uses shoes with a rocker bottom sole and custom molded insoles and intensive ambulatory check-ups.

Entities:  

Mesh:

Year:  2003        PMID: 12766126     DOI: 10.2337/diacare.26.6.1874

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  8 in total

1.  Validation of an algorithm to predict reulceration in amputation patients with diabetes.

Authors:  Raúl J Molines-Barroso; José L Lázaro-Martínez; Francisco J Álvaro-Afonso; Irene Sanz-Corbalán; José L García-Klepzig; Javier Aragón-Sánchez
Journal:  Int Wound J       Date:  2016-08-09       Impact factor: 3.315

2.  [Minor amputations for diabetic foot syndrome].

Authors:  G Rümenapf; W Lang; S Morbach
Journal:  Orthopade       Date:  2009-12       Impact factor: 1.087

3.  On the decision rules of cost-effective treatment for patients with diabetic foot syndrome.

Authors:  John E Goulionis; Athanassios Vozikis; Vk Benos; D Nikolakis
Journal:  Clinicoecon Outcomes Res       Date:  2010-08-17

4.  Incidence of re-amputation following partial first ray amputation associated with diabetes mellitus and peripheral sensory neuropathy: a systematic review.

Authors:  Sara L Borkosky; Thomas S Roukis
Journal:  Diabet Foot Ankle       Date:  2012-01-20

5.  Mini-Invasive floating metatarsal osteotomy for resistant or recurrent neuropathic plantar metatarsal head ulcers.

Authors:  Eran Tamir; Aharon S Finestone; Erez Avisar; Gabriel Agar
Journal:  J Orthop Surg Res       Date:  2016-07-11       Impact factor: 2.359

6.  Differences in initial versus recurrent diabetic foot ulcers at a specialized tertiary diabetic foot care center in China.

Authors:  Yuxia Cheng; Ping Zu; Jie Zhao; Lintao Shi; Hongyan Shi; Mei Zhang; Aihong Wang
Journal:  J Int Med Res       Date:  2021-01       Impact factor: 1.671

Review 7.  Metatarsal Head Resections in Diabetic Foot Patients: A Systematic Review.

Authors:  Irene Sanz-Corbalán; Aroa Tardáguila-García; Josep M García-Alamino; Yolanda García-Álvarez; Francisco Javier Álvaro-Afonso; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2020-06-13       Impact factor: 4.241

8.  Analysis of Plantar Pressure Pattern after Metatarsal Head Resection. Can Plantar Pressure Predict Diabetic Foot Reulceration?

Authors:  Marta García-Madrid; Yolanda García-Álvarez; Francisco Javier Álvaro-Afonso; Esther García-Morales; Aroa Tardáguila-García; José Luis Lázaro-Martínez
Journal:  J Clin Med       Date:  2021-05-24       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.